IQVIA (NYSE:IQV) Price Target Lowered to $255.00 at Barclays

IQVIA (NYSE:IQV) had its price objective trimmed by Barclays from $260.00 to $255.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has an overweight rating on the medical research company’s stock.

A number of other brokerages have also commented on IQV. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Friday. JPMorgan Chase & Co. reduced their price objective on IQVIA from $288.00 to $279.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. Truist Financial lowered their target price on IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a research note on Monday, October 14th. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group dropped their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $261.56.

IQVIA Stock Up 0.5 %

Shares of IQV opened at $210.19 on Friday. IQVIA has a 12 month low of $190.20 and a 12 month high of $261.73. The stock has a market cap of $38.32 billion, a price-to-earnings ratio of 27.58, a P/E/G ratio of 2.01 and a beta of 1.51. The company has a 50-day moving average price of $233.55 and a two-hundred day moving average price of $229.64. The company has a quick ratio of 0.85, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On IQVIA

Hedge funds have recently modified their holdings of the company. Jennison Associates LLC grew its stake in shares of IQVIA by 7.3% in the 1st quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock valued at $35,636,000 after buying an additional 9,578 shares during the period. PGGM Investments raised its position in IQVIA by 55.8% in the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after purchasing an additional 4,326 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of IQVIA by 80.1% in the first quarter. SG Americas Securities LLC now owns 45,787 shares of the medical research company’s stock valued at $11,579,000 after buying an additional 20,369 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in IQVIA during the 1st quarter valued at approximately $3,365,000. Finally, BNP Paribas acquired a new stake in shares of IQVIA during the first quarter worth $1,096,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.